本帖最后由 老马 于 2012-1-13 21:20 编辑 . ]& z# b/ h3 F, w
6 `7 y( Q R% A! _爱必妥和阿瓦斯丁的比较' W6 U$ D* Z' z0 j" S# @, H% b R; _
8 R$ T' Z0 m5 E( I
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
- U9 B7 \4 \3 a
2 w3 D9 F2 ]' U+ ]. ^
: e/ a! G/ N3 x$ K# M2 F' M
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/( v N6 C6 U/ R% J" j( F! P5 T& a
==================================================( \9 P5 _: |. H1 c8 T! c1 f: M
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)" M3 F7 K$ M: e) n3 v1 \. }
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
% E1 K: i/ ]9 d7 }, v4 DResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
) |: t- ? ^; o* z( Z9 D6 h
|